This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aytu BioScience, Inc.
Drug Names(s): Zertane + PDE-5
Zertane-ED is a combination of Zertane and a PDE-5 inhibitor with the concept that it could treat both PE and ED simultaneously.
Ampio is also developing Zertane as a stand-alone product.
Ampio and Daewoong
In September 2011, Ampio Pharmaceuticals announced a license and development agreement with Daewoong Pharmaceuticals providing Daewoong exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (PE) and for a combination drug, utilizing Zertane and another erectile dysfunction drug (PDE5 inhibitors and others), to simultaneously treat premature ejaculation and erectile dysfunction (ED).
Ampio and Vyrix
In December 2013, Ampio announced that it has spun off its sexual dysfunction business into a standalone company called Vyrix Pharmaceuticals, Inc. The new Company is expected to be funded through an initial public offering.
Vyrix assets will include Zertane and Zertane-ED, late stage mens health products from Ampios portfolio. Vyrix initial business strategy is to initiate and complete registration trials for Zertane in the US and develop worldwide commercialization and marketing partnerships....See full deal structure in Biomedtracker
Partners: Daewoong Pharmaceutical Company Ltd.
Additional information available to subscribers only: